Phio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA) therapeutic platform. Immunotherapies harness our immune system to restore surveillance of tumors that evade detection – a potential curative medicine. sd-rxRNA therapeutics can be used as a standalone treatment or in combination with other modalities.
Provided by Nasdaq.
Dec 11 - Dec 13, 2018Tumor Targeted Lymphocytes Summit
Nov 14, 2018 at 4:30 PM ESTRXi Pharmaceuticals Third Quarter 2018 Conference Call
Nov 10, 2018 from 12:20 PM to 1:50 PM EST33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC)